Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abelacimab - Anthos Therapeutics

Drug Profile

Abelacimab - Anthos Therapeutics

Alternative Names: anti-FXI mAb; FXI antibody; MAA-868

Latest Information Update: 12 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Pharmaceuticals
  • Developer Anthos Therapeutics; Labcorp Drug Development; Novartis Pharmaceuticals; TIMI Study Group
  • Class Antiarrhythmics; Anticoagulants; Antithrombotics; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Factor XI inhibitors; Factor XIa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atrial fibrillation; Venous thromboembolism
  • Phase II Stroke; Thrombosis

Most Recent Events

  • 06 Jun 2024 Data Monitoring Committee recommends an open-label extension for abelacimab
  • 18 Nov 2023 Phase-III clinical trials in Atrial fibrillation (In the elderly) in Brazil, Bulgaria, Chile, Germany, Hungary, Italy, Poland, Romania, Spain, United Kingdom (SC) (NCT05712200)
  • 12 Nov 2023 Efficacy data from a phase II AZALEA-TIMI 71 trial in Stroke released by Anthos Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top